Generic blood pressure drugs approved
The drugmaker from Canonsburg, Pa., has now received marketing approval for several doses of the drugs, but it was not able to sell them until this month. Its competitor Teva Pharmaceutical Industries Ltd. was the first company to file for approval of generic versions of the drug, so other versions were barred from the market for six months. Teva received FDA clearance in April.
The newly approved versions of the drug are ready for shipping immediately, Mylan said.
Combined, Cozaar and Hyzaar were Merck's second best selling product. Mylan said U.S. sales of Cozaar totaled $940 million over the 12 months ended June 30, while Hyzaar sales totaled $570 million. Merck's sales fell by almost half after Teva started selling its generics.
Mylan shares rose 2 cents to $18.96 in morning trading Friday.
Oct 22, 2010